

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Glycosylation, Sugar Hydrazones, and Antimicrobial Evaluation of Some 6-Substituted-1,2,4-Triazines

A. A. El-Barbary<sup>a</sup>; Y. A. Hafiz<sup>a</sup>; M. S. Abdel-Wahed<sup>a</sup>

<sup>a</sup> Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt

Online publication date: 21 December 2009

**To cite this Article** El-Barbary, A. A. , Hafiz, Y. A. and Abdel-Wahed, M. S.(2010) 'Glycosylation, Sugar Hydrazones, and Antimicrobial Evaluation of Some 6-Substituted-1,2,4-Triazines', *Nucleosides, Nucleotides and Nucleic Acids*, 29: 1, 55 — 71

**To link to this Article:** DOI: 10.1080/15257770903454482

**URL:** <http://dx.doi.org/10.1080/15257770903454482>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## GLYCOSYLATION, SUGAR HYDRAZONES, AND ANTIMICROBIAL EVALUATION OF SOME 6-SUBSTITUTED-1,2,4-TRIAZINES

A. A. El-Barbary, Y. A. Hafiz, and M. S. Abdel-Wahed

*Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt*

□ *Hydrazinolysis of 4-amino-6-[2-(4-methoxyphenyl)vinyl]-3-thioxo-3,4-dihydro-2H-[1,2,4] triazin-5-one (1) gave the corresponding hydrazino derivatives (2). Cyclocondensation of (2) with carbon disulfide furnished 8-amino-6-[2-(4-methoxyphenyl)vinyl]-3-thioxo-2,8-dihydro-3H-[1,2,4]triazolo[4,3-b][1,2,4]triazin-7-one (3) which was treated with 2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide (4) in pyridine to give the corresponding N-glucosyl derivative 5, which deblocked to give 8. Compound 2 was reacted with isatin 9 and/or isatoic anhydride 10 to afford 11 and 12. Treatment of 11 and 12 with (4) in pyridine gave the corresponding mono glucosyl derivatives 13 and 14, which were deblocked by ammonia and afforded 15 and 16. Condensation of 2 with aldoses afforded the corresponding cyclic products 17a-f and with D-fructose furnished 18. Acetylation of 17b, d afforded the corresponding polyacetyl derivatives 19b,d. Compound 2 condensed with some aromatic aldehydes in boiling methanol and gave 20a-f. The newly synthesized compounds were tested as antimicrobial agents.*

**Keywords** Hydrazinolysis; glycosides; sugar hydrazones; antibacterial activity


### INTRODUCTION

1,2,4-Triazine ring systems have been reported as potential biologically active agents.<sup>[1]</sup> As a kind of widely used biologically active compound, derivatives of triazinone compounds exhibit anticancer, antiulcer, and anti-inflammatory effects. In the agricultural field, this class of compounds shows activities, such as insecticides, herbicides, plant growth regulators, and increasing crop yields.<sup>[2,3]</sup> Moreover, 1,2,4-triazine derivatives have been investigated for some time for their effects on the central nervous system.<sup>[4–6]</sup> In the last decade, numerous fused 1,2,4-triazines have been synthesized and

Received 13 April 2009; accepted 29 October 2009.

Thanks are due to Dr. Abdel-Rehem El-Shanshory Professor of Microbiology, Botany ;Department, Faculty of Science, Tanta University, Tanta, Egypt, for Antimicrobial Testing.

Address correspondence to M. S. Abdel-Wahed, Chemistry Department, Faculty of Science, Tanta University, Tanta 31527, Egypt. E-mail: msa.paper@yahoo.com



**SCHEME 1** Synthesis of 3-hydrazino-1,2,4-triazine derivative.

screened in vitro, revealing their anti-HIV and anti-cancer activities<sup>[7–11]</sup> as well as selective weed control in wheat, antibacterial, antiviral, antifungal, anti-inflammatory, anticonvulsant activities, and carrageen induced edema inhibitor.<sup>[12–14]</sup>


## RESULTS AND DISCUSSION

Different carbohydrazides were found to be useful as medicaments especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular diseases, fever, hemorrhage, and sepsis. Carbohydrazides and related compounds exhibited antifungal, antiviral, and bacteriostatic.<sup>[15]</sup> Accordingly, hydrazinolysis of compound **1** could be achieved by its treatment with a boiling mixture of hydrazine, MeOH/DMF to afford 4-amino-3-hydrazino-6-[2-(4-methoxyphenyl)vinyl]-4*H*-[1,2,4]triazin-5-one (**2**) (Scheme 1).

Cyclocondensation of **2** with carbon disulfide in pyridine at 80°C was achieved to afford 8-amino-6-[2-(4-methoxyphenyl)vinyl]-3-thioxo-2,8-dihydro-3*H*-[1,2,4] triazolo[4,3-*b*][1,2,4]triazin-7-one (**3**). The structure of **3** was established with spectroscopic data. Its <sup>1</sup>H NMR spectrum showed a singlet at  $\delta$  8.35 assigned to NH proton, which appear at 3455 cm<sup>-1</sup> in its IR spectrum (Scheme 2).

Direct glycosidation of compound **3** was reported to offer a convenient selective synthesis of the 2-glycosyl derivative.<sup>[16,17]</sup> So, coupling of **3** with 2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide (**4**) in pyridine afforded 8-amino-6-[2-(4-methoxyphenyl) vinyl]-3-thioxo-7,8-dihydro-2-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-1,2,4-triazolo[4,3-*b*][1,2,4]triazine-7-one (**5**) as the sole product (TLC; Scheme 2).

The anomeric proton of similar  $\beta$ -N- glucosides having an adjacent C=S was reported to appear more down field than that for the  $\beta$ -S-glucosides due to the anisotropic deshielding effect of the C=S.<sup>[18–23]</sup> So the position of the anomeric proton at  $\delta$  5.25 with  $J_{1'} = 8.93$  Hz confirmed the  $\beta$ -N- structure of compound **5** and excluded the possible isomeric  $\beta$ -S- structure of compound **6**. The mass spectrum of **5** showed the parent ion peak at  $m/z = 646$  (M<sup>+</sup>, 6.30%; Scheme 2).




**SCHEME 2** Coupling of 3 with acetyl-D-glucopyranosyl bromide derivative.

Oxidation of **5** with potassium permanganate at 25°C furnished 8-amino-6-[2-(4-methoxyphenyl)vinyl]-7,8-dihydro-2-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-1,2,4-triazolo[4,3-b][1,2,4]triazine-3,7-dione (**7**), whose IR spectrum showed (2 C=O) at 1600 and 1680  $\text{cm}^{-1}$  (Scheme 3).

Deblocking of **5** was achieved by its treatment with ammonia solution at r.t to afford 8-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-thioxo-2-( $\beta$ -D- glucopyranosyl)-2,8-dihydro-3*H*-[1,2,4]triazolo[4,3-b][1,2,4]triazin-7-one (**8**). Its  $^1\text{H}$  NMR spectrum showed a doublet at  $\delta$  5.19 ppm assigned to the anomeric proton of the glucose moiety with  $J_{1'} = 9.13$  Hz according to a diaxial orientation of  $\text{H}_{1'}$  and  $\text{H}_{2'}$  protons, which confirmed its  $\beta$ -configuration<sup>[24]</sup> (Scheme 3).

The Schiff bases of isatin were investigated for their pharmaceutical properties<sup>[25]</sup> and Isatoic anhydride possesses some synthetic potential in this respect due to its ability to undergo various cyclization reactions.<sup>[26]</sup> Thus, condensation of **2** with isatin **9** and/or isatoic anhydride **10** in anhydrous boiling dioxane furnished 3-((4-amino-6-[2-(4-




SCHEME 3 Oxidation of compound 5.

methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-yl} hydrazono)-1,3-dihydro-indol-2-one (**11**) and 3-{4-amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-ylamino}-1*H*-quinazoline-2,4-dione (**12**), respectively (Scheme 4). Compounds **11** and **12** were elucidated by spectroscopic data. Thus, infrared (IR) spectrum of **11** showed, (2 CO) bands at 1613 and 1716  $\text{cm}^{-1}$  and  $^1\text{H}$  NMR spectrum showed a doublet (2H, 2 NH) at 8.45 ppm. The mass spectrum of **11** showed the parent ion peak at  $m/z = 403$  ( $\text{M}^+$ , 100%).

Similarly, IR spectrum of **12** showed, (3 CO) bands at 1500, 1595, and 1640  $\text{cm}^{-1}$  and its  $^1\text{H}$  NMR spectrum showed a singlet (2H, 2 NH) at 6.18 ppm. In addition, its mass spectrum showed the parent ion peak at  $m/z = 419$  ( $\text{M}^+$ , 17.20%; Scheme 4).

Coupling compounds **11** and/or **12** with (4) in pyridine at room temperature gave 6-[3-({4-amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-yl} hydrazono)-1-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-2,3-dihydroindole-2-one (**13**) and 6-(3-{4-amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4] triazin-3-ylamino}-1-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-1*H*-quinazoline-2,4-dione (**14**), respectively. The  $^1\text{H}$  NMR spectra of **13** and **14** showed the position of the anomeric protons at  $\delta$  4.25 and 4.67 with  $J_{1'} = 9.35$  and 9.59 Hz confirmed the  $\beta$ -N- structure of **13** and **14** in addition to the presence of OAc groups at the range 2.09–2.58 ppm. Their IR spectra showed bands at the range 1748–1750  $\text{cm}^{-1}$  (OAc; Scheme 5).

Deblocking of **13** and/or **14** was achieved by their treatment with ammonia solution at room temperature to afford 3-({4-Amino- 6-[2-(4-




**SCHEME 4** Condensation of **2** with isatin and/or isatoic anhydride.

methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4] triazin-3-yl}hydrazono)-1-( $\beta$ -D-glucopyranosyl)-1,3-dihydroindol-2-one (**15**) and 3-4-Amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4] triazin-3-ylamino}-1-( $\beta$ -D-glucopyranosyl)-1*H*-quinazoline-2,4-dione (**16**), respectively (Scheme 5). The  $^1\text{H}$  NMR spectra of **15** and **16** showed the position of the anomeric protons at  $\delta$  4.82 and 4.80 ppm with  $J_{1'} = 9.18$  and 9.23 Hz confirmed the  $\beta$ -N-structure of **15** and **16** in addition to the presence of (OH) groups at the range 3.38–3.97 ppm. Their IR spectra showed bands at the range 3396–3746  $\text{cm}^{-1}$  (OH) (Scheme 5).

Compound **2** was reacted with some aldoses namely, D-glucose, D-galactose, D-mannose, D-ribose, L-arabinose and/or D-xylose in anhydrous boiling dioxane to yield the corresponding sugar hydrazones 4-amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(polyhydroxyhexylidene)hydrazinyl]-4*H*-[1,2,4]triazin-5-one **17a–f** (Scheme 6).

The structure of compounds **17a–f** was confirmed by spectral evidences. The  $^1\text{H}$  NMR spectra showed structure **17a–f** fitted with the recorded data. For example, the  $^1\text{H}$  NMR spectrum of **17a** showed a signal at 5.72 ppm (1H) corresponded to (NH) proton and a signal at 7.69 ppm (1H) corresponded to  $\text{CH=N}$ . The  $^1\text{H}$  NMR spectra of **17b–f** showed similar patterns to that discussed above (Scheme 6).

Similarly, compound **2** reacted with D-fructose under the same reaction conditions to give 4-amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2,3,4,5-




**SCHEME 5** Coupling of 11 and/or 12 with acetyl-D-glucopyranosyl bromide derivative.


tetrahydroxy-1-hydroxymethylpentylidene)hydrazine]-4H-[1,2,4]triazin-5-one (**18**) (Scheme 7).

Acetylation of the sugar hydrazones **17b,d** with acetic anhydride in anhydrous pyridine at room temperature afforded the polyacetyl derivatives **19b,d** (Scheme 8). The  $^1\text{H}$  NMR spectra of the products **19b,d** confirmed the presence of OAc groups in addition to the NAc group. Their IR spectra showed bands at 1630–1670 (NAc) and 1684–1746  $\text{cm}^{-1}$  (OAc).


Compound **2** condensed with some aromatic aldehydes in boiling methanol and gave the corresponding hydrazones **20a–f**. Their structures could be assigned as two tautomeric forms **i** and **ii**. Both tautomers were observed in the  $^1\text{H}$  NMR spectra where the signals correspond to the



Downloaded At: 19:12 25 January 2011




Downloaded At: 19:12 25 January 2011



Downloaded At: 19:12 25 January 2011





**SCHEME 9** Condensation of **2** with some aldehydes.

CH–NH and CH=N groups are all present. This indicates the presence of a ring-chain tautomerism and the two tautomers coexist in a dynamic equilibrium (Scheme 9).

As an example, the <sup>1</sup>H NMR spectrum of compound **20a** showed a signal at 5.42 ppm corresponds to NH<sub>2</sub> protons and a signal at 10.41 ppm corresponds to CH=N proton. Its IR spectrum showed a sharp band at 3238 cm<sup>−1</sup> attributed to the presence of NH<sub>2</sub> group.

## BIOLOGICAL ACTIVITY

The newly synthesized compounds were screened for their *in vitro* antibacterial activities using the cut plug method<sup>[27]</sup> against the gram positive bacteria (*Bacillus subtilius* and *Staphylococcus aureus*) and the gram negative bacteria (*Escherichia coli*, *Salmonella typhae*, and *Klebsilla sp.*) and antifungal activity against yeast (*Candida albicans*) using Chloramphenicol and Streptomycin as standard drugs. The results are summarized and illustrated in Table 1.

The results revealed that most of the tested compounds showed antibacterial or/and antifungal (anticandidal) activity with varying magnitudes. The zone of inhibition above 7 mm in diameters was taken as a positive result.

Compounds **17a–f** and **18** showed low antimicrobial activities, except **17c**. The effect differed according to the presence of polyhydroxy side chain.

Compound **20e** showed only antibacterial but not antifungal activity. On the other hand, compound **20f** showed the highest antibacterial and antifungal effect may be due to the presence of a pyridyl ring.

**TABLE 1** Diameters of inhibition zones (mm) of newly synthesized triazines against different test bacteria on nutrient agar and yeast after 24 hours by the cut-plug method on nutrient agar at 35–37°C

Cpd.	Tasted organisms					
	<i>Escherichia coli</i>	<i>Bacillus subtilus</i>	<i>Staphylococcus aureus</i>	<i>Salmonella typhae</i>	<i>Klebsilla sp.</i>	<i>Candida albicans</i>
Chloramophenicol (30 µgm)	20	20	38	—	23	—
Streptomycin (10 µgm)	14	23	12	—	11	—
(1)	12	—	—	10	12	10
(2)	10	20	15	10	20	25
(3)	17	20	25	17	17	25
(5)	17	17	—	13	15	20
(8)	17	10	—	17	17	15
(11)	—	—	—	—	—	—
(12)	9	7	—	—	—	10
(13)	10	—	10	—	—	—
(14)	—	—	—	—	—	—
(15)	—	9	—	—	15	10
(16)	10	9	—	—	10	15
(17a)	15	13	11	13	12	13
(17b)	13	12	12	11	—	12
(17c)	—	—	—	—	—	—
(17d)	15	20	15	15	15	15
(17e)	—	—	10	—	—	11
(17f)	—	—	—	13	—	12
(18)	17	8	20	10	13	20
(19b)	15	17	18	13	15	10
(19d)	—	—	—	15	—	15
(20a)	—	—	—	—	—	—
(20b)	—	—	—	—	—	—
(20c)	—	—	—	—	—	—
(20d)	8	—	—	—	—	8
(20e)	10	12	11	10	—	—
(20f)	40	35	25	45	35	40

## EXPERIMENTAL

All melting points are uncorrected and performed by the open capillary melting point apparatus. Microanalyses were performed by Microanalysis Unit, Faculty of Science, Tanta University, Egypt. IR spectra were recorded with a Perkin-Elmer spectrometer (Perkin-Elmer, Waltham, MA, USA). The NMR spectra were recorded on a Bruker 300 MHz and Bruker 200 MHz spectrometer (Bruker, Bellerica, MA, USA) using TMS as an internal standard, DMSO and CHCl<sub>3</sub> as solvents. Mass spectra (MS) were recorded using electron ionization (E.I.) on a Varian Mat 311A spectrometer.

Compound 1 was prepared according to literature method.<sup>[28]</sup>

Compound 2 was prepared according to literature method.<sup>[29]</sup>

**8-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-thioxo-2,8-dihydro-3H [1,2,4]triazolo [4,3-b][1,2,4]triazin-7-one (3)**

Compound **2** (2.74 g, 0.01 mol) and carbon disulfide (10 ml) in anhydrous pyridine (25 ml) was refluxed for 5 hours (TLC). The solvent was removed under vacuo and the residue was refluxed for 1 hour in acetic acid and cooled, the solid product formed was filtered off, and recrystallized from DMF/EtOH to give compound **3**. (72.8%); m.p. 151–152°C; **IR** (**KBr**), 1601 (CN), 2933 (CH), 3455 (NH)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  (DMSO- $d_6$ ):  $\delta$  3.75 (s, 3H,  $\text{CH}_3\text{O}$ -4), 3.82 (s, 2H,  $\text{NH}_2$ ), 7.11–7.93 (m, 6H,  $\text{H}_{\text{arom}}$ ), 8.35 (s, 1H, NH).

Anal. For  $\text{C}_{13}\text{H}_{12}\text{N}_6\text{O}_2\text{S}$  Calcd.: C, 49.36; H, 3.82; N, 26.57. Found: C, 49.33; H, 3.79; N, 26.48.

**8-amino-6-[2-(4-methoxyphenyl)vinyl]-3-thioxo-7,8-dihydro-2-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-1,2,4-triazolo[4,3-b][1,2,4]triazine-7-one (5)**

To a suspension of compound **3** (3.16g, 0.01 mol) in anhydrous pyridine (15 ml), 2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide (**4**) (4.1g, 0.01 mol) was added with stirring and cooling to 10°C over a period of 10 minutes. The stirring was continued at room temperature overnight (TLC). The reaction mixture was poured onto ice water. The solid obtained was filtered off, dried and recrystallized from DMF to afford **5**. (61%); m.p. 219–220°C; **MS**:  $m/z$  646 ( $\text{M}^+$ , 6.30); **IR** (**KBr**), 1603 (CN), 1640 (C = ON), 1783 (C = OO)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  (DMSO- $d_6$ )  $\delta$  2.15, 2.27, 2.29, 2.37 (4s, 12H, 4Ac), 3.53 (s, 3H,  $\text{OCH}_3$ ), 3.95 (dd, 1H,  $J_{\text{H-5'-H-4'}} = 2.13 \text{ Hz}$ ,  $J_{\text{H-5'-H-5''}} = 11.23 \text{ Hz}$ , H-5'), 4.11 (t, 1H,  $J = 2.33 \text{ Hz}$ , H-4'), 4.53 (dd, 1H,  $J_{\text{H-3'-H-4'}} = 3.19 \text{ Hz}$ ,  $J_{\text{H-3'-H-2'}} = 10.00 \text{ Hz}$ , H-3'), 4.99 (dd, 1H,  $(J_{\text{H-2'-H-1'}} + J_{\text{H-2'-H-3'}})/2 = 7.14 \text{ Hz}$ , H-2'), 5.25 (d, 1H,  $J' = 8.93$ , H-1'), 5.61 (s, 2H,  $\text{NH}_2$ ), 7.44–7.89 (m, 6H,  $\text{H}_{\text{arom}}$ ).

Anal. For  $\text{C}_{27}\text{H}_{30}\text{N}_6\text{O}_{11}\text{S}$  Calcd.: C, 50.15; H, 4.68; N, 12.75. Found: C, 50.07; H, 4.63; N, 13.00.

**8-amino-6-[2-(4-methoxyphenyl)vinyl]-7,8-dihydro-2-(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)-1,2,4-triazolo[4,3-b][1,2,4]triazine-3,7-dione (7)**

To a solution of **5** (6.46 g, 0.01 mol) in glacial acetic acid (25 ml), a solution of potassium permanganate (0.3 g, 0.02 mol) in water (10 ml) was added gradually with stirring for 30 minutes. Stirring was continued for 5 hours at room temperature, and the mixture was then poured onto crushed ice. The resulting solid was collected and recrystallized from DMF to afford **7**. (65%); m.p. 232–235°C; **IR** (**KBr**), 1600 and 1680 (2 CO), 2987 (CH), 3183 ( $\text{NH}_2$ )  $\text{cm}^{-1}$ .

Anal. For  $C_{27}H_{30}N_6O_{12}$  Calcd.: C, 51.43; H, 4.80; N, 13.33. Found: C, 51.22; H, 4.73; N, 13.09.

**8-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-thioxo-2-( $\beta$ -D-glucopyranosyl)-2,8-dihydro-3H-[1,2,4]triazolo[4,3-b][1,2,4]triazin-7-one (8)**

Stirring of compound **5** (6.46 g, 0.01 mol) in ammonia solution (20 ml) overnight until the starting material was consumed (TLC). The solid obtained was filtered, dried and recrystallized from ethanol to afford **8**. (78%); m.p. 195–196°C; **IR** (KBr), 1614 (CN), 3353 (NH<sub>2</sub>), 3499 (OH)  $cm^{-1}$ ; **<sup>1</sup>H NMR** (DMSO-*d*<sub>6</sub>)  $\delta$  3.71 (s, 3H, OCH<sub>3</sub>), 4.08–4.47 (m, 4H, 4OH), 4.55 (dd, 1H, *J* = 7.08 Hz, H-5'), 4.91 (d, 1H, *J* = 2.37 Hz, H-4'), 5.09 (d, 1H, *J* = 2.98 Hz H-3'), 5.19 (d, 1H, *J* = 9.13 Hz H-1', 2'), 5.28 (s, 2H, NH<sub>2</sub>), 5.38 and 5.54 (s, 2H, H-1', 2'), 7.68–8.23 (m, 6H, H<sub>arom</sub>).

Anal. For  $C_{19}H_{22}N_6O_7S$  Calcd.: C, 47.69; H, 4.63; N, 17.44. Found: C, 47.55; H, 4.57; N, 17.44.

**Reaction of 2 with Isatin and Isatoic Anhydride: Formation of 11 and 12**

A mixture of **2** (2.74 g, 0.01 mol) and isatin or isatoic anhydride (0.01 mol) was refluxed in dioxane (25 ml) for 3–5 hours (TLC). The solvent was removed under vacuo and the residue was recrystallized from DMF/water to give **11** and **12**, respectively.

**3-({4-Amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-yl} hydrazono)-1,3-dihydro-indol-2-one (11)**. (96%); m.p. > 300°C; **MS**: *m/z* 403 (*M*<sup>+</sup>, 100); **IR** (KBr), 1613 and 1716 (2CO), 3212 (NH<sub>2</sub>), 3303 (NH)  $cm^{-1}$ ; **<sup>1</sup>H NMR** (DMSO-*d*<sub>6</sub>)  $\delta$  3.42 (s, 3H, CH<sub>3</sub>O-4), 5.67 (s, 2H, NH<sub>2</sub>), 6.81 (t, 2H, *J* = 4.4 Hz, H<sub>arom</sub>), 7.18 (t, 2H, *J* = 7.7 Hz, H<sub>arom</sub>), 7.54 (d, 2H, *J* = 3.6 Hz, H<sub>arom</sub>), 7.61 (q, 2H, *J* = 4.3 Hz, H<sub>arom</sub>), 7.76 (d, 2H, *J* = 8.3 Hz, H<sub>arom</sub>), 8.45 (d, 2H, 2NH), 10.59 (s, 1H, OH). Anal. For  $C_{20}H_{17}N_7O_3$  Calcd.: C, 59.55; H, 4.25; N, 24.31. Found: C, 59.47; H, 4.17; N, 24.22.

**3-{4-Amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-ylamino}-1H-quinazoline-2,4-dione (12)**. (80%); m.p. 284–286°C; **MS**: *m/z* 419 (*M*<sup>+</sup>, 17.20); **IR** (KBr), 1500, 1595 and 1640 (3CO), 3263 (NH<sub>2</sub>), 3437 (NH)  $cm^{-1}$ ; **<sup>1</sup>H NMR** (DMSO-*d*<sub>6</sub>)  $\delta$  3.45 (s, 3H, CH<sub>3</sub>O-4), 5.23 (s, 2H, NH<sub>2</sub>), 6.18 (s, 2H, 2NH), 7.25–7.78 (m, 10H, H<sub>arom</sub>). Anal. For  $C_{20}H_{17}N_7O_4$  Calcd.: C, 57.28; H, 4.09; N, 23.38. Found: C, 57.12; H, 4.19; N, 22.86.

### Reaction of Compound 11 and/or 12 with (4): Formation of 13 and 14

To a suspension of compounds **11** and/or **12** (0.01 mol) in anhydrous pyridine (15 ml), (4) (4.1g, 0.01 mol) was added with stirring and cooling to 10°C over a period of 10 minutes. The stirring was continued at room temperature overnight (TLC). The reaction mixture was poured onto ice, and the solid obtained was filtered off, dried, and recrystallized from DMF to afford **13** and **14**.

**6-[3-({4-amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-yl}hydrazono)-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-2,3-dihydroindole-2-one (13).** (63%); m.p. 260–262°C; IR (KBr), 1605 (CN), 1750 (C=OO), 3424 (NH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.38, 2.43, 2.49, 2.58 (4s, 12H, 4Ac), 3.22 (s, 3H, CH<sub>3</sub>O-4), 3.82 (s, 2H, NH<sub>2</sub>), 4.11–4.25 (m, 7H, H<sub>pyran</sub>, *J*<sub>1'</sub> = 9.35 Hz), 6.99–7.23 (m, 4H, H<sub>arm</sub>), 7.25–7.48 (m, 6H, H<sub>arm</sub>), 8.23 (s, 1H, NH). Anal. For C<sub>34</sub>H<sub>35</sub>N<sub>7</sub>O<sub>12</sub> Calcd.: C, 55.66; H, 4.81; N, 13.36. Found: C, 55.23; H, 4.79; N, 13.27.

**6-(3-{4-amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-ylamino}-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-1H-quinazoline-2,4-dione (14).** (50%); m.p. 269–270°C; IR (KBr), 1626 (CN), 1691 (C = O), 1748 (C = OO) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.09, 2.18, 2.23, 2.26 (4s, 12H, 4Ac), 3.14 (s, 3H, CH<sub>3</sub>O-4), 3.92 (s, 2H, NH<sub>2</sub>), 4.21, 4.36, 4.45, 4.59, 4.67 (5s, 7H, H<sub>pyran</sub>, *J*<sub>1'</sub> = 9.59 Hz), 6.60–6.88 (m, 10H, H<sub>arom</sub>), 8.13 (s, 1H, NH). Anal. For C<sub>35</sub>H<sub>37</sub>N<sub>7</sub>O<sub>13</sub> Calcd.: C, 55.04; H, 4.80; N, 12.84. Found: C, 55.11; H, 4.69; N, 12.77.

### Deblocking of Compounds 13 and/or 14

Compounds **13** and/or **14** (0.01 mol) were stirred at room temperature with ammonia solution (20 ml) over night (TLC). The solid obtained was filtered off, dried and recrystallized from ethanol to afford **15** and **16**.

**3-({4-Amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-yl}hydrazono)-1-(β-D-glucopyranosyl)-1,3-dihydroindol-2-one (15).** (81%); m.p. 209–211°C; IR (KBr), 1592 (CN), 3238 (NH<sub>2</sub>), 3392 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 3.15 (s, 3H, CH<sub>3</sub>O-4), 3.38–3.72 (m, 4H, OH), 4.08 (s, 2H, NH<sub>2</sub>), 4.33, 4.42, 4.51, 4.69 and 4.82 (5s, 7H, H<sub>pyran</sub>, *J*<sub>1'</sub> = 9.18 Hz), 6.39–6.58 (m, 4H, H<sub>arom</sub>), 6.61–6.78 (m, 6H, H<sub>arm</sub>), 7.91 (s, 1H, NH). Anal. For C<sub>26</sub>H<sub>27</sub>N<sub>7</sub>O<sub>8</sub> Calcd.: C, 55.22; H, 4.81; N, 17.34. Found: C, 54.98; H, 4.77; N, 17.14.

**3-{4-Amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro[1,2,4]triazin-3-ylamino}-1-(β-D-glucopyranosyl)-1H-quinazoline-2,4-dione (16).** (89%); m.p. 225–226°C; IR (KBr), 1595 (CN), 3398 (NH<sub>2</sub>), 3746 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 3.24 (s, 3H, CH<sub>3</sub>O-4), 3.57–3.97 (m, 4H, OH), 4.18 (s, 2H, NH<sub>2</sub>), 4.41, 4.57, 4.61, 4.63 and 4.80 (5s, 7H, H<sub>pyran</sub>, *J*<sub>1'</sub> = 9.23

Hz), 6.71–6.89 (m, 4H, H<sub>arom</sub>), 6.92–7.10 (m, 6H, H<sub>arom</sub>), 8.07 (s, 1H, NH). Anal. For C<sub>27</sub>H<sub>29</sub>N<sub>7</sub>O<sub>9</sub> Calcd.: C, 54.45; H, 4.91; N, 16.46. Found: C, 54.33; H, 4.87; N, 16.18.

## Condensation of 2 with Free Sugars: Formation of 17a–f and 18

### General Procedure

A mixture of **2** (2.74 g, 0.01 mol) and aldohexoses, namely: D-glucose, D-galactose, D-mannose, aldopentoses, namely: D-ribose, L-arabinose, D-xylose, and/or fructose (0.01 mol) was refluxed in dioxane (20 ml) for 4 hours (TLC). After cooling, the precipitated solid was filtered off, washed with ethanol and recrystallized from DMF to afford **17a–f** and **18**.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2,3,4,5,6-pentahydroxy-hexylidene)hydrazine]-4H-[1,2,4]triazin-5-one (17a).** Using D-glucose in the general procedure gave **17a**. (82%); m.p. 195–196°C; IR (KBr), 1600 (CN), 3208 (NH<sub>2</sub>), 3425 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.51 (s, 3H, CH<sub>3</sub>O-4), 3.67–3.75 (m, 4H, OH), 3.89 (s, 1H, OH), 4.35 (d, 2H, *J* = 5.36 Hz, H-5'), 4.49 (dd, 1H, *J* = 2.97 Hz, H-4'), 4.85 (dd, 1H, *J*<sub>H-3'-H-4'</sub> = 2.18 Hz, *J*<sub>H-3'-H-2'</sub> = 9.36 Hz, H-3'), 5.03 (t, 1H, *J* = 2.07, H-2'), 5.25 (s, 2H, NH<sub>2</sub>), 5.68 (d, 1H, *J* = 2.78, H-1'), 5.72 (s, H, NH), 6.91–7.13 (m, 6H, H<sub>arom</sub>), 7.69 (s, 1H, N = CH). Anal. For C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O<sub>7</sub> Calcd.: C, 49.54; H, 5.54; N, 19.26. Found: C, 49.98; H, 5.72; N, 18.67.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2,3,4,5,6-pentahydroxy-hexylidene)hydrazine]-4H-[1,2,4]triazin-5-one (17b).** Using D-galactose in the general procedure gave **17b**. (88%); m.p. 177–179°C; MS: *m/z* 436 (M<sup>+</sup>, 16.30); IR (KBr), 1590 (CN), 3248 (NH<sub>2</sub>), 3368 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.95 (s, 3H, CH<sub>3</sub>O-4), 4.11–4.58 (m, 5H, OH), 4.77 (m, 2H, H-5'), 5.38 (d, 1H, *J* = 2.76 Hz, H-4'), 5.61 (d, 1H, *J* = 2.99 Hz, H-3'), 5.91 (d, 1H, *J* = 2.33 Hz, H-2'), 6.11 (d, 1H, *J* = 2.93 Hz, H-1'), 6.35 (s, 2H, NH<sub>2</sub>), 6.62 (s, H, NH), 7.38–7.63 (m, 6H, H<sub>arom</sub>), 8.38 (s, 1H, N = CH). Anal. For C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O<sub>7</sub> Calcd.: C, 49.54; H, 5.54; N, 19.26. Found: C, 49.38; H, 5.49; N, 19.16.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2,3,4,5,6-pentahydroxy-hexylidene)hydrazine]-4H-[1,2,4]triazin-5-one (17c).** Using D-mannose in the general procedure gave **17c**. (76%); m.p. 183–185°C; MS: *m/z* 436 (M<sup>+</sup>, 25.10); IR (KBr), 1593 (CN), 3375 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.74 (s, 3H, CH<sub>3</sub>O-4), 3.67–4.22 (m, 5H, OH), 4.55 (d, 2H, *J* = 6.53 Hz, H-5'), 4.92 (d, 1H, *J* = 5.19 Hz, H-4'), 5.25 (dd, 1H, *J*<sub>H-3'-H-4'</sub> = 4.57 Hz, *J*<sub>H-3'-H-2'</sub> = 12.76 Hz, H-3'), 5.55 (t, 1H, *J* = 4.49, H-2'), 5.75 (d, 1H, *J* = 7.55, H-1'), 6.00 (s, 2H, NH<sub>2</sub>), 6.42 (s, H, NH), 7.06–7.44 (m, 6H, H<sub>arom</sub>), 8.09 (s, 1H, N = CH). Anal. For C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O<sub>7</sub> Calcd.: C, 49.54; H, 5.54; N, 19.26. Found: C, 49.43; H, 5.52; N, 19.20.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2,3,4,5-tetrahydroxypentylidene)hydrazine]-4H-[1,2,4]triazin-5-one (17d).** Using D-ribose in the

general procedure gave **17d**. (85%); m.p. 170–171°C; **IR** (**KBr**), 1595 (CN), 3210 (NH<sub>2</sub>), 3266 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.51 (s, 3H, CH<sub>3</sub>O-4), 3.69–3.75 (m, 4H, 4OH), 4.42 (d, 1H, *J* = 5.83 Hz, H-4'), 4.61 (s, 1H, H-3'), 4.75 (t, *J* = 4.86 Hz, H-2'), 4.91 (d, 1H, *J* = 3.19 Hz, H-1'), 5.03 (s, H, NH), 5.24 (s, 2H, NH<sub>2</sub>), 6.89–7.55 (m, 6H, H<sub>arom</sub>), 7.74 (s, 1H, N = CH). Anal. For C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>6</sub> Calcd.: C, 50.24; H, 5.46; N, 20.68. Found: C, 50.11; H, 5.42; N, 20.60.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2,3,4,5-tetrahydroxypentylidene) hydrazine]-4H-[1,2,4]triazin-5-one (17e)**. Using L-arabinose in the general procedure gave **17e**. (60%); m.p. 200–201°C; **IR** (**KBr**), 1597 (CN), 3319 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.78 (s, 3H, CH<sub>3</sub>O-4), 3.65–4.08 (m, 4H, OH), 4.35 (t, 1H, *J* = 6.85 Hz, H-4'), 4.62 (t, 1H, *J* = 5.27 Hz, H-3'), 4.82 (d, 1H, *J* = 3.49 Hz, H-2'), 4.96 (d, 1H, *J* = 5.99 Hz, H-1'), 5.19 (s, H, NH), 5.51 (s, 2H, NH<sub>2</sub>), 6.74–7.45 (m, 6H, H<sub>arom</sub>), 7.68 (s, 1H, N = CH). Anal. For C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>6</sub> Calcd.: C, 50.24; H, 5.46; N, 20.68. Found: C, 50.23; H, 5.41; N, 20.44.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2,3,4,5-tetrahydroxypentylidene) hydrazine]-4H-[1,2,4]triazin-5-one (17f)**. Using D-xylose in the general procedure gave **17f**. (79%); m.p. 172–173°C; **IR** (**KBr**), 1601 (CN), 3267 (NH<sub>2</sub>), 3449 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.50 (s, 3H, CH<sub>3</sub>O-4), 3.41–3.78 (m, 4H, 4OH), 4.11 (d, 1H, *J* = 5.66 Hz, H-4'), 4.38 (m, 1H, H-3'), 4.75 (d, 1H, *J* = 6.43 Hz, H-2'), 5.02 (d, 1H, *J* = 2.83 Hz, H-1'), 5.23 (s, H, NH), 5.53 (s, 2H, NH<sub>2</sub>), 6.92–7.55 (m, 6H, H<sub>arom</sub>), 7.73 (s, 1H, N = CH). Anal. For C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>6</sub> Calcd.: C, 50.24; H, 5.46; N, 20.68. Found: C, 50.19; H, 5.39; N, 20.53.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(1,2,3,4-tetrahydroxy-1-hydroxy- methylpentylidene)hydrazine]-3H-[1,2,4]triazin-5-one (18)**. Using D-fructose in the general procedure gave **18**. (76%); m.p. 192–194°C; **IR** (**KBr**), 1599 (CN), 3251 (NH<sub>2</sub>), 3423 (OH) cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 2.49 (s, 3H, CH<sub>3</sub>O-4), 3.59–4.12 (m, 5H, OH), 4.84 (d, 1H, *J* = 6.09 Hz, H-4'), 5.11 (m, 1H, H-3'), 5.45 (d, 1H, *J* = 5.77 Hz, H-2'), 5.61 (d, 1H, *J* = 4.53 Hz, H-1'), 5.85 (s, 2H, NH<sub>2</sub>), 6.42 (s, H, NH), 6.82–7.21 (m, 6H, H<sub>arom</sub>). Anal. For C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O<sub>7</sub> Calcd.: C, 49.54; H, 5.54; N, 19.26. Found: C, 49.36; H, 5.51; N, 19.07.

### Acetylation of **17b,d**: Formation of **19b,d**

To a suspension of each of **17b,d** (0.01 mol) in anhydrous pyridine (10 ml), acetic anhydride (7 ml) was added dropwise with stirring and cooling to 10°C over a period of 10 minutes. The stirring was continued at room temperature overnight (TLC). The reaction mixture was poured onto ice water. The solid obtained was filtered off, dried, and recrystallized from ethanol to afford compounds **19b,d**.

**Acetic acid 2,3-diacetoxy-4-(acetyl-[4-amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro-[1,2,4]triazin-3-yl]hydrazono)-1-(1,2-diacetoxyethyl) butyl ester (19b).** (65%); m.p. 214–215°C; **IR** (KBr), 1609 (CN), 1630 (C = ON), 1684 (C = OO)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  (DMSO- $d_6$ )  $\delta$  2.43–2.98 (6s, 18H, 6Ac), 3.68 (s, 3H,  $\text{CH}_3\text{O-4}$ ), 4.43 (dd, 2H,  $J = 7.38$  Hz, H-5'), 4.78 (t, 1H,  $J = 2.38$  Hz, H-4'), 4.81 (dd, 1H,  $J_{\text{H-3'-H-4'}} = 1.88$  Hz,  $J_{\text{H-3'-H-2'}} = 10.57$  Hz, H-3'), 5.23 (dd, 1H,  $(J_{\text{H-2-H-1'}} + J_{\text{H-2-H-3}})/2 = 1.77$  Hz, H-2'), 5.45 (d, 1H,  $J = 2.29$ , H-1'), 5.51 (d, 1H,  $J = 2.73$ , H-3), 5.82 (s, 2H,  $\text{NH}_2$ ), 6.80–7.60 (m, 6H,  $\text{H}_{\text{arom}}$ ). Anal. For  $\text{C}_{30}\text{H}_{36}\text{N}_6\text{O}_{13}$  Calcd.: C, 52.32; H, 5.27; N, 12.20. Found: C, 52.06; H, 5.13; N, 11.87.

**Acetic acid 2,3-diacetoxy-1-acetoxymethyl-4-(acetyl-[4-amino-6-[2-(4-methoxyphenyl)vinyl]-5-oxo-4,5-dihydro-[1,2,4]triazin-3-yl]hydrazono)butyl ester (19d).** (70%); m.p. 247–249°C; MS:  $m/z$  616 ( $\text{M}^+$ , 2.30); **IR** (KBr), 1614 (CN), 1670 (C = ON), 1746 (C = OO)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  (DMSO- $d_6$ )  $\delta$  1.79–2.23 (m, 12H, 4 $\text{CH}_3\text{CO}$ , 4Ac), 2.51 (s, 3H,  $\text{NCOCH}_3$ ), 3.68 (s, 3H,  $\text{CH}_3\text{O-4}$ ), 3.45 (s, 2H,  $\text{NH}_2$ ), 4.91 (m, 1H,  $J = 5.73$ , H-5'), 5.22 (d, 1H,  $J = 3.18$  Hz, H-4'), 5.81 (d, 1H,  $J = 4.54$  Hz H-3'), 6.17 (s, 2H, H-1', 2'), 6.22 (d, 1H,  $J = 3.33$ , H-3), 6.92–7.61 (m, 6H,  $\text{H}_{\text{arom}}$ ). Anal. For  $\text{C}_{27}\text{H}_{32}\text{N}_6\text{O}_{11}$  Calcd.: C, 52.60; H, 5.23; N, 13.63. Found: C, 52.49; H, 5.27; N, 13.61.

### Condensation of Compound 2 with Aldehydes: Formation of 20a–f

A mixture of compound **2** (2.74 g, 0.01 mol) and some aromatic aldehydes, namely: benzaldehyde, 4-methoxybenzaldehyde, 4-hydroxybenzaldehyde, 2-nitrobenzaldehyde, thiophene-2-carboxaldehyde and/or pyridine-2-carboxaldehyde (0.01 mol) was refluxed in methanol (40 ml) for 2 hr (TLC) and cooled to room temperature the precipitated solid was filtered off, washed with ethanol and recrystallized from DMF/water mixture to afford compounds **20a–f**, respectively.

**4-Amino-3-(N'-benzylidenehydrazino)-6-[2-(4-methoxyphenyl)vinyl]-4H-[1,2,4] triazin-5-one (20a taut i).** (89%), m.p. 230–233°C, **IR** (KBr), 1586 (CN), 2967 (CH), 3238 ( $\text{NH}_2$ ), 3482 (NH)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ ): 3.81 (s, 3H,  $\text{CH}_3\text{O-4}$ ), 5.42 (s, 2H,  $\text{NH}_2$ ), 6.81 (d, 1H,  $J = 2.78$  Hz,  $\text{CH-NH}$ , *tautomer ii*), 7.32 (s, 1H, NH), 7.40–7.82 (m, 9H,  $\text{H}_{\text{arom}}$ ), 8.4 (s, 1H,  $\text{HN-N} = \text{C}$ ), 10.40 (s, 1H,  $\text{CH} = \text{N}$ ). Anal. For  $\text{C}_{19}\text{H}_{18}\text{N}_6\text{O}_2$  Calcd.: C, 62.97; H, 5.01; N, 23.19. Found: C, 62.83; H, 4.97; N, 23.27.

**4-Amino-3-[N'-(4-methoxybenzylidene)hydrazino]-6-[2-(4-methoxyphenyl)vinyl]-4H-[1,2,4]triazin-5-one (20b taut i).** (98%), m.p. 240–241°C, **IR** (KBr), 1602 (CN), 2927 (CH), 3401 (NH)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  3.81 (s, 6H, 2 $\text{CH}_3\text{O-4}$ ), 5.40 (s, 2H,  $\text{NH}_2$ ), 7.00 (m, 5H,  $\text{H}_{\text{arom}}$ ), 7.12 (d, 1H,  $J = 2.59$  Hz,  $\text{CH-NH}$ , *tautomer ii*), 7.50–7.93 (m, 6H,  $\text{H}_{\text{arom}}$ ), 8.43 (s, 1H,  $\text{HN-N} = \text{C}$ ), 10.22 (s, 1H,  $\text{CH} = \text{N}$ ). Anal. For  $\text{C}_{20}\text{H}_{20}\text{N}_6\text{O}_3$  Calcd.: C, 61.22; H, 5.14; N, 21.42. Found: C, 61.07; H, 5.11; N, 21.39.



**4-Amino-3-[N'-(4-hydroxybenzylidene)hydrazino]-6-[2-(4-methoxyphenyl)vinyl]-4H-[1,2,4]triazin-5-one (20c taut i).** (94%), m.p. 262–264°C, IR (KBr), 1595 (CN), 2931 (CH), 3316 (NH)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ ): 3.82 (s, 6H,  $2\text{CH}_3\text{O-4}$ ), 4.38 (s, 1H, OH), 5.73 (s, 2H,  $\text{NH}_2$ ), 6.88–7.38 (m, 4H,  $\text{H}_{\text{arom}}$ ), 7.50 (d, 1H,  $J = 2.49$  Hz,  $\text{CH-NH}$ , *tautomer ii*), 7.18–7.99 (m, 6H,  $\text{H}_{\text{arom}}$ ), 8.81 (s, 1H,  $\text{HN-N} = \text{C}$ ), 10.22 (s, 1H,  $\text{CH} = \text{N}$ ). Anal. For  $\text{C}_{19}\text{H}_{18}\text{N}_6\text{O}_3$  Calcd.: C, 60.31; H, 4.79; N, 22.21. Found: C, 60.19; H, 4.58; N, 22.18.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-[N'-(2-nitrobenzylidene)hydrazino]-4H-[1,2,4]triazin-5-one (20d taut i).** (90%), m.p. 283–285°C, IR (KBr), 1612 (CN), 1343 ( $\text{NO}_2$ ), 3424 (NH)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ ): 3.84 (s, 3H,  $\text{CH}_3\text{O-4}$ ), 5.51 (s, 2H,  $\text{NH}_2$ ), 6.96 (m, 4H,  $\text{H}_{\text{arom}}$ ), 7.13 (d, 1H,  $J = 2.33$  Hz,  $\text{CH-NH}$ , *tautomer ii*), 7.53–8.22 (m, 6H,  $\text{H}_{\text{arom}}$ ), 8.83 (s, 1H,  $\text{HN-N} = \text{C}$ ), 10.21 (s, 1H,  $\text{CH} = \text{N}$ ). Anal. For  $\text{C}_{19}\text{H}_{17}\text{N}_7\text{O}_4$  Calcd.: C, 56.02; H, 4.21; N, 24.07. Found: C, 55.58; H, 4.01; N, 24.64.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-(N'-thiophen-2-ylmethylenehydrazino)-4H-[1,2,4]triazin-5-one (20e taut i).** (93%), m.p. 255–256°C, IR (KBr), 1601 (CN), 3085 (Ph), 3309 ( $\text{NH}_2$ ), 3444 (NH)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ ): 3.22 (s, 3H,  $\text{CH}_3\text{O-4}$ ), 5.71 (s, 2H,  $\text{NH}_2$ ), 6.90 (d, 1H,  $J = 2.81$  Hz,  $\text{CH-NH}$ , *tautomer ii*), 7.2 (m, 5H,  $\text{H}_{\text{arom}}$ ), 7.51–7.80 (m, 6H,  $\text{H}_{\text{arom}}$ ), 8.8 (s, 1H,  $\text{HN-N} = \text{C}$ ), 10.32 (s, 1H,  $\text{CH} = \text{N}$ ). Anal. For  $\text{C}_{17}\text{H}_{16}\text{N}_6\text{O}_2\text{S}$  Calcd.: C, 55.42; H, 4.38; N, 22.81. Found: C, 55.19; H, 4.27; N, 22.93.

**4-Amino-6-[2-(4-methoxyphenyl)vinyl]-3-(N'-pyridin-2-ylmethylenehydrazino)-4H-[1,2,4]triazin-5-one (20f taut i).** (93%), m.p. 242–243°C, IR (KBr), 1606 (CN), 3055 (Ph), 3213 ( $\text{NH}_2$ ), 3400 (NH)  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ ): 3.73 (s, 3H,  $\text{CH}_3\text{O-4}$ ), 5.59 (s, 2H,  $\text{NH}_2$ ), 6.81–7.23 (m, 4H,  $\text{H}_{\text{arom}}$ ), 7.44 (d, 1H,  $J = 2.79$  Hz,  $\text{CH-NH}$ , *tautomer ii*), 7.88 (m, 6H,  $\text{H}_{\text{arom}}$ ), 8.43 (s, 1H,  $\text{HN-N} = \text{C}$ ), 10.43 (s, 1H,  $\text{CH} = \text{N}$ ). Anal. For  $\text{C}_{18}\text{H}_{17}\text{N}_7\text{O}_2$  Calcd.: C, 59.50; H, 4.72; N, 26.98. Found: C, 59.35; H, 4.69; N, 26.87.

## REFERENCES

1. Ravindra, R.; Belgur, S. Synthesis, spectral characterization and antihaemostatic activity of 1,2,4-triazoles incorporating 1,2,4-triazine rings. *J. Chem. Sci.* **2006**, 118(2), 191–195.
2. Yang, R.; Kaplan, P.A. Reaction of isothiourea with 2,3-diaza-3-pentenedioic anhydride. A solid-phase synthesis of 3-amino-1,2,4-triazin-5(4H)-ones. *Tetra. Lett.* **2001**, 42(27), 4433–4435.
3. Hua, Z.; Jihong, L.; Qiang, X. Synthesis and characterization of novel derivatives of Triazinone. *Front. Chem. China* **2007**, 2(2), 164–168.
4. Palmer, R.A.; Potter, B.S.; Leach, M.J.; Chowdhry, B.Z. Low temperature x-ray crystallographic structures of two lamotrigine analogues: (I) 2-Methyl,3-amino, 5-imino-6-(2,3-dichlorophenyl)-1,2,4-triazine water solvate and (II) 2-methyl,3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate, hemi-hydrate. *J. Chem. Crystallogr.* **2008**, 38, 255–260.
5. Palmer, R.A.; Potter, B.S.; Leach, M.J.; Chowdhry, B.Z. X-ray crystallographic structures of neuroprotective pyrimidine derivatives: (I) The mesylate salt of BW1003C87 and (II) sipatrigine base. *J. Chem. Crystallogr.* **2007**, 37, 771–777.
6. Riddall, D.R.; Leach, M.J.; Garthwaite, J. A novel drug binding site on voltage-gated sodium channels in rat brain. *Mol Pharmacol.* **2006**, 69(1), 278–287.

7. Hwang, L.; Tu, C.; Wang, J.; Lee, G. Synthesis and molecular structure of 6-amino-3-benzylmercapto-1,2,4-triazolo[3,4-*f*][1,2,4]triazin-8(7*H*)-one. *Molecules*, **2006**, 11, 169–176.
8. Abdel-Rahman, R.M.; Morsy, J.M.; Hanafy, F. Synthesis of heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anticancer drugs: Part I. *Pharmazie* **1999**, 54, 347–351.
9. El-Gendy, Z.; Morsy, J.M.; Allimony, H.A.; Ali, W.R.; Abdel-Rahman, R.M. *Pharmazie* **2001**, 56, 376.
10. Holla, B.S.; Rao, B.S.; Gonsalves, R.; Sarojini, B.K.; Shridhara, K. Synthesis of some new biologically active thiadiazolotriazinones—Part III. *Farmaco*, **2002**, 57, 693–696.
11. Nyffenegger, C.; Fournet, G.; Joseph, B. Synthesis of 3-amino-5H-pyrrolo [2,3-*c*]-1,2,4-triazines by Sonogashira/copper(I)-catalyzed heteroannulation. *Tetrahedron Lett.* **2007**, 48, 5069–5072.
12. El Ashry, E.S.H.; Rashed, N.; Taha, M.; Ramadan, E. Condensed 1,2,4-triazines: I. Fused to heterocycles with three-, four-, and five-membered Rings. *Adv. Heterocycl. Chem.* **1994**, 59, 39–177.
13. El Ashry, E.S.H.; Rashed, N.; Mousaad, A.; Ramadan, E. Condensed 1,2,4-Triazines: II. Fused to heterocycles with six- and seven-membered rings and fused to two heterocyclic rings. *Adv. Heterocycl. Chem.* **1994**, 61, 207–328.
14. El-Gendy, Z.; Morsy, J.M.; Allimony, H.A.; Abdel-Monem Ali, W.R.; Abdel-Rahman, R.M. Synthesis of heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anticancer drugs, part III. *Pharmazie*, **2001**, 56, 376–381.
15. Mansour, A.K.; Eid, M.M.; Khalil, N.S. Synthesis and reactions of some new heterocyclic carbonylhydrazides and related compounds as potential anticancer agents. *Molecules* **2003**, 8, 744–755.
16. Ibrahim, Y.A. Facile approach for the selective glycosidation of cyclic asymmetric amides and thioamides. *Carbohydr. Lett.* **1996**, 1, 425–432.
17. Mansour, A.K.; Ibrahim, Y.A.; Khalil, N.S.A.M. Selective synthesis and structure of 6-arylvinyl-2- and 4-glucosyl-1,2,4-triazines of expected interesting biological activity. *Nucleosides Nucleotides* **1999**, 18 (10), 2256–2283.
18. Rashed, N.; Abdel Hamid, H.; Ramadan, E.; ElAshry, E.S.H. acyclo *C*-nucleoside analogs. regioselective annellation of a triazole ring to 5-methyl-1,2,4-triazino[5,6-*b*]indole and formation of certain 3-poly hydroxyalkyl derivatives. *Nucleosides, Nucleotides Nucleic Acids* **1998**, 17, 1373–1384.
19. Mansour, A.K.; Eid, M.M.; Khalil, N.S.A.M. Selective synthesis and reactions of 6-substituted-2-b-galactosyl-1,2,4-triazines of potential anticancer activity. *Nucleosides, Nucleotides Nucleic Acids* **2003**, 22(1), 21–44.
20. Mansour, A.K.; Eid, M.M.; Khalil, N.S.A.M. Synthesis of some new 2- $\alpha$ -L-arabinopyranosyl-1,2,4-triazines of potential anticancer activity. *Nucleosides Nucleotides Nucleic Acids* **2003**, 22(9), 1805–1823.
21. Mansour, A.K.; Ibrahim, Y.A.; Eid, M.M.; Abdel-Hady, S.A.L. N-Glucosyl derivatives of some 1,2,4-triazines with tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide. *J. Carbohydr. Nucleosides Nucleotides* **1981**, 8(2), 81–99.
22. Mansour, A.K.; Ibrahim, Y.A.; Eid, M.M. Nucleoside derivatives of 1,2,4-triazine. Reaction of some derivatives of 1,2,4-triazine with tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide. *Z. Naturforsch.* **1976**, 31b, 505–508.
23. Eid, M.M.; Abdel-Hady, S.A.L.; Ali, H.A.W. Reaction of some 1,2,4-triazines with acetobromoglucose. *Arch. Pharm.* **1990**, 323(4), 243–245.
24. Ibrahim, Y.A.; Abbas, A.A.; Elwahy, A.H.M. Selective synthesis and structure of 2-N- and 3-S-glucosyl-1,2,4-triazoles of potential biological interest. *Carbohydr. Lett.* **1999**, 3, 331–338.
25. Jarrahpour, A.A.; Khalili, D. Synthesis of 3,3'-[methylenebis(3,1-phenylenenitrilo)]bis[1,3-dihydro]-2H-indol-2-one as a novel bis-Schiff base *Molbank* **2005**, 4, 437.
26. Shikhaliev, Kh. S.; Kryl'skii, D.V.; Shestakov, A.S.; Falaleev, A.V.; Condensation of isatoic anhydride with tetarylguanidines. *Russian Journal of General Chemistry*, **2003**, 73(7), 1147–1150.
27. Pridham, T.G.; Shotwell, O.L.; Stodola, F.H.; Lindeufelser, L.A.; Benedict, R.G.; Jackson, R.W. *Phytopathology*. **1956**, 46, 575.
28. Eid, M.M.; Hassan, R.H. Synthesis and condensation reactions of some 6-substituted-benzyl-3-hydrazino-2,5-dihydro-1,2,4-triazin-5-ones. *J. Pharm. Sci.* **1990**, 31, 337–342.
29. Badawy, M.A. Synthesis and reactions of 1,2,4-triazino-1,2,4-triazines. *Sulfur Lett.* **1990**, 11, 21–28.